Results from the dual Phase III TRIUMpH trials demonstrated the statistical superiority of tegoprazan over lansoprazole in ...

Braintree Laboratories, a part of Sebela Pharmaceuticals® and a leading manufacturer of gastroenterology pharmaceutical products, today announced positive topline results from two pivotal US Phase 3 ...

Sebela Pharma announces positive results from phase 3 TRIUMpH programme of tegoprazan in GERD: Braintree, Massachusetts Friday, April 25, 2025, 18:00 Hrs [IST] Braintree Laborator ...

The Phase 3 EE study consisted of a large, multi-center, double-blind study (n=1,250, including 463 patients with LA Grade C/D esophagitis) evaluating the safety and efficacy of tegoprazan versus ...

“Tegoprazan offers an exciting new treatment option for individuals suffering from GERD, helping to address the substantial unmet need of patients not well-controlled by conventional PPI therapy,” ...

This cohort included 78 people with a normal esophagus, 77 with BE, 12 with high-grade dysplasia, five with low-grade dysplasia, one with indeterminate dysplasia and 61 with esophageal adenocarcinoma.

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious pipeline development ...

In Haiti’s gang-held zones, CHFF offers hope through health, education and youth jobs to counter violence and despair.